Patent intelligence · US
US 8946205
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
Patent details — US 8946205
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 3, 2015
- Expiration
- Jan 29, 2035
- Applicant
- Addex Pharma, S.A.
- Claims
- 25
- CPC classes
- A61K, A61K31/437, A61K31/444, A61K31/553
Quick answer
US 8946205 (1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors) is held by Addex Pharma, S.A.. Status: granted. Granted Feb 3, 2015. Expires Jan 29, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Addex Pharma, S.A.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/437, A61K31/444, A61K31/553, A61K45/06, A61K9/0014
More from Addex Pharma, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 11071729
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted -
US 10071095
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
granted -
US 9938270
Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor
granted -
US 9765091
Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors
granted -
US 9737533
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9266834
1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
granted -
US 9226930
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9132122
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted
Frequently asked questions
What is US patent 8946205?
US 8946205 (1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors) is held by Addex Pharma, S.A.. Status: granted. Granted Feb 3, 2015. Expires Jan 29, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8946205?
Addex Pharma, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 8946205 expire?
Our index shows an expiration date of Jan 29, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.